Silverfin false false 31/01/2026 01/02/2025 31/01/2026 Mrs M Sadikeen Armstrong Grimshaw 30/04/2015 Mrs C Armstrong-Entwistle 01/03/2021 Mr M Gatenby 30/04/2015 Mr B Miller 06/05/2019 30 June 2026 The principal activity of the company is the wholesaling of pharmaceuticals and chemists' sundries. 09569508 2026-01-31 09569508 bus:Director1 2026-01-31 09569508 bus:Director2 2026-01-31 09569508 bus:Director3 2026-01-31 09569508 bus:Director4 2026-01-31 09569508 2025-01-31 09569508 core:CurrentFinancialInstruments 2026-01-31 09569508 core:CurrentFinancialInstruments 2025-01-31 09569508 core:Non-currentFinancialInstruments 2026-01-31 09569508 core:Non-currentFinancialInstruments 2025-01-31 09569508 core:ShareCapital 2026-01-31 09569508 core:ShareCapital 2025-01-31 09569508 core:SharePremium 2026-01-31 09569508 core:SharePremium 2025-01-31 09569508 core:RetainedEarningsAccumulatedLosses 2026-01-31 09569508 core:RetainedEarningsAccumulatedLosses 2025-01-31 09569508 core:OtherResidualIntangibleAssets 2025-01-31 09569508 core:OtherResidualIntangibleAssets 2026-01-31 09569508 core:PlantMachinery 2025-01-31 09569508 core:Vehicles 2025-01-31 09569508 core:FurnitureFittings 2025-01-31 09569508 core:ComputerEquipment 2025-01-31 09569508 core:PlantMachinery 2026-01-31 09569508 core:Vehicles 2026-01-31 09569508 core:FurnitureFittings 2026-01-31 09569508 core:ComputerEquipment 2026-01-31 09569508 core:CostValuation 2025-01-31 09569508 core:CostValuation 2026-01-31 09569508 core:ProvisionsForImpairmentInvestments 2025-01-31 09569508 core:ProvisionsForImpairmentInvestments 2026-01-31 09569508 core:WithinOneYear 2026-01-31 09569508 core:WithinOneYear 2025-01-31 09569508 core:BetweenOneFiveYears 2026-01-31 09569508 core:BetweenOneFiveYears 2025-01-31 09569508 2025-02-01 2026-01-31 09569508 bus:FilletedAccounts 2025-02-01 2026-01-31 09569508 bus:SmallEntities 2025-02-01 2026-01-31 09569508 bus:AuditExempt-NoAccountantsReport 2025-02-01 2026-01-31 09569508 bus:PrivateLimitedCompanyLtd 2025-02-01 2026-01-31 09569508 bus:Director1 2025-02-01 2026-01-31 09569508 bus:Director2 2025-02-01 2026-01-31 09569508 bus:Director3 2025-02-01 2026-01-31 09569508 bus:Director4 2025-02-01 2026-01-31 09569508 core:OtherResidualIntangibleAssets 2025-02-01 2026-01-31 09569508 core:PlantMachinery 2025-02-01 2026-01-31 09569508 core:Vehicles core:TopRangeValue 2025-02-01 2026-01-31 09569508 core:FurnitureFittings 2025-02-01 2026-01-31 09569508 core:ComputerEquipment core:TopRangeValue 2025-02-01 2026-01-31 09569508 2024-02-01 2025-01-31 09569508 core:Vehicles 2025-02-01 2026-01-31 09569508 core:ComputerEquipment 2025-02-01 2026-01-31 09569508 core:PlantMachinery 1 2025-02-01 2026-01-31 09569508 core:Vehicles 1 2025-02-01 2026-01-31 09569508 core:FurnitureFittings 1 2025-02-01 2026-01-31 09569508 core:ComputerEquipment 1 2025-02-01 2026-01-31 09569508 1 2025-02-01 2026-01-31 09569508 core:Subsidiary1 2025-02-01 2026-01-31 09569508 core:Subsidiary1 1 2025-02-01 2026-01-31 09569508 core:Subsidiary1 1 2024-02-01 2025-01-31 iso4217:GBP xbrli:pure decimalUnit

Company No: 09569508 (England and Wales)

C. D. MEDICAL LIMITED

Unaudited Financial Statements
For the financial year ended 31 January 2026
Pages for filing with the registrar

C. D. MEDICAL LIMITED

Unaudited Financial Statements

For the financial year ended 31 January 2026

Contents

C. D. MEDICAL LIMITED

COMPANY INFORMATION

For the financial year ended 31 January 2026
C. D. MEDICAL LIMITED

COMPANY INFORMATION (continued)

For the financial year ended 31 January 2026
DIRECTORS Mrs M Sadikeen Armstrong Grimshaw
Mrs C Armstrong-Entwistle
Mr M Gatenby
Mr B Miller
REGISTERED OFFICE Unit F Lostock Office Park Lynstock Way
Lostock
Bolton
BL6 4SG
United Kingdom
COMPANY NUMBER 09569508 (England and Wales)
ACCOUNTANT AAB
Carlyle House
78 Chorley New Road
Bolton
BANKERS Barclays Bank PLC
PO Box 357
51 Mosley Street
Manchester
M2 3HQ
C. D. MEDICAL LIMITED

INDEPENDENT ACCOUNTANTS' ASSURANCE REVIEW REPORT TO THE DIRECTORS OF C.D. MEDICAL LIMITED

For the financial year ended 31 January 2026
C. D. MEDICAL LIMITED

INDEPENDENT ACCOUNTANTS' ASSURANCE REVIEW REPORT TO THE DIRECTORS OF C.D. MEDICAL LIMITED (continued)

For the financial year ended 31 January 2026

We have reviewed the financial statements of C.D. Medical Limited for the year ended 31 January 2026, which comprise the Profit and Loss Account, the Balance Sheet and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102, "The Financial Reporting Standard applicable in the UK".

This report is made solely to the company’s directors, as a body, in accordance with the terms of our engagement letter. Our review has been undertaken so that we may state to the company’s directors those matters we have agreed with them in our engagement letter and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s directors as a body for our work, for this report, or for the conclusions we have formed.

DIRECTORS' RESPONSIBILITY FOR THE FINANCIAL STATEMENTS

The directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

ACCOUNTANTS' RESPONSIBILITY

Our responsibility is to express a conclusion based on our review of the financial statements. We conducted our review in accordance with International Standard on Review Engagements (ISRE) 2400 (Revised), Engagements to review historical financial statements and ICAEW Technical Release TECH 09/13AAF Assurance review engagements on historical financial statements. ISRE 2400 also requires us to comply with ICAEW Code of Ethics.

SCOPE OF THE ASSURANCE REVIEW

A review of financial statements in accordance with the ISRE 2400 (Revised) is a limited assurance engagement. We have performed additional procedures to those required under a compilation engagement. These primarily consist of making enquiries of management and others within the entity, as appropriate, applying analytical procedures and evaluating the evidence obtained. The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with International Standards on Auditing (UK). Accordingly, we do not express an audit opinion on these financial statements.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the financial statements have not been prepared:

• so as to give a true and fair view of the state of the company’s affairs as at 31 January 2026, and of its profit for the year ended;
• in accordance with United Kingdom Generally Accepted Accounting Practice applicable to Smaller Entities; and
• in accordance with the requirements of the Companies Act 2006.

C. D. MEDICAL LIMITED

BALANCE SHEET

As at 31 January 2026
C. D. MEDICAL LIMITED

BALANCE SHEET (continued)

As at 31 January 2026
Note 2026 2025
£ £
Fixed assets
Intangible assets 4 91,455 86,877
Tangible assets 5 40,607 88,477
132,062 175,354
Current assets
Stocks 643,766 423,483
Debtors 7 974,596 702,072
Cash at bank and in hand 220,161 701,039
1,838,523 1,826,594
Creditors: amounts falling due within one year 8 ( 464,996) ( 492,277)
Net current assets 1,373,527 1,334,317
Total assets less current liabilities 1,505,589 1,509,671
Creditors: amounts falling due after more than one year 9 0 ( 19,816)
Net assets 1,505,589 1,489,855
Capital and reserves
Called-up share capital 10,530 10,530
Share premium account 140,000 140,000
Profit and loss account 1,355,059 1,339,325
Total shareholders' funds 1,505,589 1,489,855

For the financial year ending 31 January 2026 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of C. D. Medical Limited (registered number: 09569508) were approved and authorised for issue by the Board of Directors on 30 June 2026. They were signed on its behalf by:

Mr B Miller
Director
C. D. MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 January 2026
C. D. MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 January 2026
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

C. D. Medical Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Unit F Lostock Office Park Lynstock Way, Lostock, Bolton, BL6 4SG, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Profit and Loss Account in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Turnover

Turnover represents amounts receivable for goods provided in the normal course of business, and is shown net of VAT. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probably that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Employee benefits

Short term benefits
The cost of short-term employee benefits are recognised as a liability and an expense.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised as an expense when the Company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Defined contribution schemes
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets is reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Intangible assets

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Other intangible assets 5 % reducing balance
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery 15 % reducing balance
Vehicles 4 years straight line
Fixtures and fittings 15 % reducing balance
Computer equipment 4 years straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Leases

The Company as lessee
Assets held under finance leases, hire purchase contracts and other similar arrangements, which confer rights and obligations similar to those attached to owned assets, are capitalised as tangible fixed assets at the fair value of the leased asset (or, if lower, the present value of the minimum lease payments as determined at the inception of the lease) and are depreciated over the shorter of the lease terms and their useful lives. The capital elements of future lease obligations are recorded as liabilities, while the interest elements are charged to the Profit and Loss Account over the period of the leases to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals under operating leases are charged on a straight-line basis over the lease term, even if the payments are not made on such a basis. Benefits received and receivable as an incentive to sign an operating lease are similarly spread on a straight-line basis over the lease term.

Impairment of assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recognised impairment losses are reversed, if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost includes materials, direct labour and an attributable proportion of manufacturing overheads based on normal levels of activity. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Equity instruments
Equity instruments issued by the Company are recorded at the fair value of cash or other resources received or receivable, net of direct issue costs. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the Company.

Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the Balance Sheet date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

2. Critical accounting judgements and key sources of estimation uncertainty

In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3. Employees

2026 2025
Number Number
Monthly average number of persons employed by the Company during the year, including directors 20 16

4. Intangible assets

Other intangible assets Total
£ £
Cost
At 01 February 2025 108,780 108,780
Additions 10,500 10,500
At 31 January 2026 119,280 119,280
Accumulated amortisation
At 01 February 2025 21,903 21,903
Charge for the financial year 5,922 5,922
At 31 January 2026 27,825 27,825
Net book value
At 31 January 2026 91,455 91,455
At 31 January 2025 86,877 86,877

5. Tangible assets

Plant and machinery Vehicles Fixtures and fittings Computer equipment Total
£ £ £ £ £
Cost
At 01 February 2025 36,758 21,980 131,328 28,375 218,441
Additions 0 0 0 8,434 8,434
Disposals 0 0 ( 64,500) ( 3,114) ( 67,614)
At 31 January 2026 36,758 21,980 66,828 33,695 159,261
Accumulated depreciation
At 01 February 2025 23,764 21,980 70,191 14,029 129,964
Charge for the financial year 2,526 0 9,687 6,842 19,055
Disposals 0 0 ( 27,792) ( 2,571) ( 30,363)
Transfer 0 0 ( 3,577) 3,575 ( 2)
At 31 January 2026 26,290 21,980 48,509 21,875 118,654
Net book value
At 31 January 2026 10,468 0 18,319 11,820 40,607
At 31 January 2025 12,994 0 61,137 14,346 88,477

6. Fixed asset investments

Investments in subsidiaries

2026
£
Cost
At 01 February 2025 100
At 31 January 2026 100
Provisions for impairment
At 01 February 2025 100
At 31 January 2026 100
Carrying value at 31 January 2026 0
Carrying value at 31 January 2025 0

Investments in shares

Details of the company's subsidiaries at 31 January 2026 are as follows:

Name of entity Registered office Principal activity Class of
shares
Ownership
31.01.2026
Ownership
31.01.2025
Held
C D Medical (Bolton) Limited Unit F Lynstock Office Park, Bolton Dormant Ordinary 100.00% 100.00% Direct

7. Debtors

2026 2025
£ £
Trade debtors 896,213 637,741
Other debtors 78,383 64,331
974,596 702,072

8. Creditors: amounts falling due within one year

2026 2025
£ £
Trade creditors 173,196 217,823
Other taxation and social security 117,484 59,143
Other creditors 174,316 215,311
464,996 492,277

Obligations under hire purchase contracts are secured on the assets to which they relate.

9. Creditors: amounts falling due after more than one year

2026 2025
£ £
Other creditors 0 19,816

10. Financial commitments

Commitments

Total future minimum lease payments under non-cancellable operating leases are as follows:

2026 2025
£ £
Within one year 48,011 89,795
Between one and five years 27,369 32,893
75,380 122,688

11. Related party transactions

Transactions with related parties
During the year the company entered into the following transactions with related parties:

The company was charged £68,567 (2025: £129,800) for consultancy services from Quince Orchard Limited, a company which is controlled by Mr B Miller, a director of C.D. Medical Limited. As at 31 January 2026, an amount of £5,280 was outstanding (2025 - £12,500).

Included within other creditors amount due within one year is an amount of £90,820 (2025 - £178,713) due to Mrs E M Sadikeen Armstrong Grimshaw, a director. The advance is interest free and there are no fixed terms for repayment.

C.D. Medical Limited recharged purchases and wages costs of £75,640 to a company owned by a director and shareholder. The balance owed by this company as at 31 January 2026 is £151,055 (2025 - £117,903).

As at 31 January 2026 staff loan balances to related parties of directors / shareholders of CD Medical Ltd was nil (2025 - £4.6k).